Chugai partners with Osaka University in £62 million immunology collaboration
pharmafile | May 20, 2016 | News story | Medical Communications, Research and Development | Chugai, collaboration, immunology, osaka university
Chugai Pharmaceuticals (TOKYO: 4519) has announced a collaboration agreement with Osaka University in advanced immunology research worth up to £62 million.
The partnership will combine the expertise in immunology, live imaging and bioinformatics of the Osaka University Immunology Frontier Center and Chugai’s aim of utilising middle molecule technologies to focus on the research and development of first-in-class pharmaceuticals. Through the collaboration, the pair hopes to eradicate the obstacles between basic research and clinical application research.
Chugai will provide one billion yen a year for 10 years in return for access to information on the results of independent basic research projects and the right of first refusal for joint research. In addition, a collaboration promotion laboratory will be set up at the university to implement joined-up research towards clinical application.
The overall aim is to have five to 10 joint research projects in progress on a constant basis.
Osamu Nagayma, chairman and CEO at Chugai, says: “Chugai has innovative proprietary technologies for antibody engineering and middle molecules, which enables drug discovery of targets that could not be done previously. Through the combination of these technologies and the diverse research results achieved through the global top-class immunology research at IFReC, we are confident of providing multiple innovative pharmaceuticals to patients.”
Sean Murray
Related Content
EVerZom enters research and licensing agreement with GENFIT
EVerZom, a French biotech company developing exosome-based therapies for regenerative medicine, has entered into a …
Custom Pharmaceuticals launches new company for drug product development
Customs Pharmaceuticals, a full-service contract development and manufacturing organisation (CDMO), has launched Centrix Pharma Solutions, …
Chronic spontaneous urticaria – the impact on patient quality of life, ongoing developments in treatments and the importance of greater awareness
The current forms of immunotherapy, how T cell therapy works and what the future holds
